Ipamorelin

Batch #453212Batch # 453212
Report #53450Report # 53450
Tested at10.98mgTested at 10.98mg
Size: 10mg
Money Back Guarantee Money Back Guarantee
Satisfaction Guarantee Satisfaction Guarantee
Easy Returns Easy Returns
Secure Ordering Secure Ordering
2-Day Shipping 2-Day Shipping
Third Party Tested Third Party Tested
Batch & Lot Tracking Batch & Lot Tracking

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About Ipamorelin

Ipamorelin operates by stimulating the pituitary gland to produce growth-related secretions in animal studies. Additionally it has been observed to reduce the production of somatostatin a secretion that can inhibit growth hormone release. Research also indicates that Ipamorelin may enhance the production of IGF-1 (Insulin-like Growth Factor 1) which is associated with processes involved in the growth and repair of muscular and skeletal tissues.

Product Specifications

Ipamorelin Lyophilized Powder in 3ml vial.

Application

Research peptide evaluated in growth hormone secretion and peptide receptor studies

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C38H49N9O5

PubChem CID

9831659

CAS Number

170851-70-4

Molecular Weight

711.86 g/mol

Synonyms

Ipamorelin

Storage

Store at ≤25°C, sealed, away from heat, light, and moisture.

1) Clinical Overview

Ipamorelin is a synthetic, selective agonist of the ghrelin (growth-hormone secretagogue) receptor GHS-R1a that triggers pulsatile growth hormone (GH) release with minimal off-target pituitary effects compared with older GHRPs. Mechanistically, it engages the ghrelin receptor on somatotrophs to amplify GH pulses and, secondarily, raise IGF-1. Early pharmacology work emphasized its selectivity for GH over ACTH/cortisol relative to GHRP-2/-6 (preclinical and translational data)  . In human volunteers, single-dose PK/PD studies confirm rapid, transient GH stimulation after short infusions of ipamorelin  .

Beyond endocrine effects, ipamorelin (as a ghrelin-receptor agonist) has been explored for gastrointestinal motility and other applications; however, clinical development for postoperative ileus was discontinued after a negative phase 2 trial  .

2) Human Clinical Findings

a) Healthy volunteers (PK/PD):

A dose-escalation study in healthy men (five 15-min IV infusion rates) found dose-proportional PK and a single GH pulse peaking ~0.67 h post-dose, then declining rapidly. Model-based analysis showed ipamorelin stimulated GH across all dose levels, with short terminal half-life (~2 h) for the drug itself  .

b) Post-operative ileus (phase 2 RCT):

In a multicenter, double-blind, placebo-controlled trial (NCT00672074), adults after bowel resection received IV ipamorelin 0.03 mg/kg twice daily up to 7 days. The primary endpoint (time to tolerate a standardized solid meal) did not differ significantly vs placebo (median 25.3 h vs 32.6 h; p=0.15). Safety was acceptable; development for this indication was halted due to lack of efficacy  .

3) Mechanism & Effects

Receptor pharmacology: Ipamorelin binds GHS-R1a (ghrelin receptor) to enhance physiologic GH pulsatility; classic reviews summarize GHS-R signaling (e.g., PLC/IP₃ pathways) and the clinical development arc of ghrelin agonists.

Selectivity: Comparative work (notably in swine) showed ipamorelin increased GH without the ACTH/cortisol rises seen with GHRP-2/-6, supporting a more GH-selective profile than earlier GHRPs  .

Skeletal effects (preclinical): In rodents, ipamorelin increased bone mineral content and counteracted glucocorticoid-induced reductions in bone formation, consistent with GH/IGF-1–mediated anabolism  .

GI motility (mixed): Ghrelin-mimetic activity can accelerate GI transit in animals, but ipamorelin failed to improve recovery endpoints in a human postoperative ileus RCT  

4) Safety & Considerations

Short-term exposure in controlled settings (healthy volunteers; surgical inpatients) was generally well tolerated, with no major safety differences vs placebo in the ileus RCT. Ipamorelin is not FDA-approved for any human indication; in 2024, FDA’s compounding advisory review concluded evidence of effectiveness is limited and noted the negative phase 2 trial (development discontinued). The agency also flagged insufficient data for other routes and indications  .

For athletes, growth-hormone secretagogues (including ipamorelin) are prohibited under the WADA S2 class of banned substances  .

References 

  1. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin… in human volunteers. Pharm Res. 1999;16(9):1412–1416. 
  2. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized… ipamorelin for postoperative ileus. Int J Colorectal Dis. 2014;29:1527–1534. 
  3. Raun K, Hansen BS, Johansen PB, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(6):552–561. (preclinical/translation; GH selectivity) 
  4. Ishida J, Saito T. Growth hormone secretagogues: history, mechanism… Receptors Clin Investig. 2020;7:e009. (review) 
  5. Smith RG, Van der Lely AJ, et al. Development of Growth Hormone Secretagogues. Endocr Rev. 2005;26(3):346–370. 
  6. Svensson J, Lall S, Dickson SL, et al. Ipamorelin and GHRP-6 increase bone mineral content in adult female rats. J Endocrinol. 2000;165(3):569–577. 
  7. Andersen NB, Malmlöf K, Johansen PB, et al. Ipamorelin counteracts glucocorticoid-induced decrease in bone formation in adult rats. Growth Horm IGF Res. 2001;11(5):266–272. 
  8. FDA Pharmacy Compounding Advisory Committee. October 29, 2024 Meeting (ipamorelin summary). 
  9. World Anti-Doping Agency (WADA). 2025 Prohibited List (S2: GHS incl. ipamorelin). 

You ask,
we answer.